Rice Jason, Ottensmeier Christian H, Stevenson Freda K
Genetic Vaccine Group, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton,SO16 6YD, UK.
Nat Rev Cancer. 2008 Feb;8(2):108-20. doi: 10.1038/nrc2326.
DNA vaccination has suddenly become a favoured strategy for inducing immunity. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, has always been attractive. However, the apparent failure to translate operational success in preclinical models to the clinic, for reasons that are now rather obvious, reduced initial enthusiasm. Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer.
DNA疫苗接种突然成为诱导免疫的一种热门策略。基于基因的疫苗所提供的分子精准性,以及纳入额外基因以指导和增强免疫的便利性,一直颇具吸引力。然而,由于现在已相当明显的原因,在临床前模型中的操作成功未能转化至临床,这降低了最初的热情。最近,新型递送系统,尤其是电穿孔,克服了这一转化障碍。在此,我们评估用于癌症治疗的DNA疫苗的发展、当前性能及潜力。